The Center for International Blood and Marrow Transplant Research (CIBMTR) is a clinical research program dedicated to addressing important issues in hematopoietic cell transplantation (HCT) by offering a unique resource of data and statistical expertise to the scientific community. The CIBMTR includes > 400 HCT centers that share data on HCT outcomes and a Statistical Center that maintains a clinical database with information for more than 250,000 HCT recipients. These data and the analytic support available through the CIBMTR Statistical Center have led to successful completion of hundreds of studies. U24-CA76518 provides the primary support for these activities. This application requests funding for the next 5 years to support this resource in order to provide the biomedical community continued access to a high quality clinical database and statistical support to facilitate clinical research. Planned resource enhancements include development of electronic data acquisition technology to facilitate participation by a wide range of U.S. and non-U.S. HCT centers; collaboration with other domestic and international organizations to increase the data available to study transplantation for rare indications and new HCT technologies; collecting data on outcome of other therapeutic applications of hematopoietic stem cells; expanding data on late effects and long-term quality of life; and developing new biostatistical methodology to address the challenges, needs and opportunities in analyzing HCT outcomes. The CIBMTR is committed to meeting the needs of investigators in a rapidly evolving field. It has and will build on the infrastructure made possible by support from U24-CA76518 and partnership with others to better serve the research community. Activities during the current and previous funding cycles have led to not only many publications on important issues in HCT but also have created the opportunity for greatly expanded global collaboration in data exchange and observational HCT research and contributed substantially to the success of a U.S. multicenter clinical trials network in HCT. Enhancements already in progress and planned for the next funding cycle will allow more in-depth exploration of immunobiologic aspects of HCT and post-HCT QOL. In summary, the CIBMTR, with the support provided through U24-CA76518, continues to play a unique role in facilitating clinical research in HCT. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
2U24CA076518-11
Application #
7476626
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (J1))
Program Officer
Merritt, William D
Project Start
1998-03-01
Project End
2013-02-28
Budget Start
2008-06-27
Budget End
2009-02-28
Support Year
11
Fiscal Year
2008
Total Cost
$3,082,752
Indirect Cost
Name
Medical College of Wisconsin
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Stiff, Patrick J; Montesinos, Pau; Peled, Tony et al. (2018) Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biol Blood Marrow Transplant 24:1463-1470
Hill, Brian T; Ahn, Kwang Woo; Hu, Zhen-Huan et al. (2018) Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. Biol Blood Marrow Transplant 24:581-586
Pulsipher, Michael A; Logan, Brent R; Chitphakdithai, Pintip et al. (2018) Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biol Blood Marrow Transplant :
Ahn, Kwang Woo; Kim, Soyoung (2018) Variable selection with group structure in competing risks quantile regression. Stat Med 37:1577-1586
Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825
Drobyski, William R; Szabo, Aniko; Zhu, Fenlu et al. (2018) Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica 103:717-727
Sullivan, Keith M; Majhail, Navneet S; Bredeson, Christopher et al. (2018) Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 24:1961-1964
Stroncek, David F; Shaw, Bronwen E; Logan, Brent R et al. (2018) Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biol Blood Marrow Transplant 24:175-184
Kumar, Anita J; Kim, Soyoung; Hemmer, Michael T et al. (2018) Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Adv 2:1022-1031
Alousi, Amin; Wang, Tao; Hemmer, Michael T et al. (2018) Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biol Blood Marrow Transplant :

Showing the most recent 10 out of 641 publications